← Back to Analyst Consensus 
AKTS Buy
Aktis Oncology, Inc.
Current Price —
Implied Upside —
Analysts 16
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 2, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Sep 9, 2026 | Oppenheimer | initiate | — → Outperform | — | 52% |
| Aug 19, 2026 | Wedbush | initiate | — → Outperform | — | 58% |
| Aug 19, 2026 | BMO Capital | initiate | — → Outperform | — | 53% |
| Jul 14, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 54% |
| Jun 16, 2026 | Raymond James | initiate | — → Strong Buy | — | 54% |
| Jun 2, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Apr 29, 2026 | William Blair | initiate | — → Outperform | — | 48% |
| Mar 31, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 9, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Feb 3, 2026 | Leerink Partners | initiate | — → Outperform | $31 | 51% |
| Feb 3, 2026 | JP Morgan | initiate | — → Overweight | $30 | 54% |
| Jan 4, 2024 | Piper Sandler | downgrade | Overweight → Neutral | $1 | 54% |
| Sep 7, 2023 | Oppenheimer | maintain | Outperform → Outperform | $3 | 52% |
| Sep 7, 2023 | B. Riley Securities | downgrade | Buy → Neutral | $1.75 | 55% |
| May 9, 2023 | Oppenheimer | maintain | — → Outperform | $6 | 52% |
| May 9, 2023 | Roth MKM | maintain | — → Buy | $5 | 52% |
| Jan 24, 2023 | B. Riley Securities | initiate | — → Buy | $9.25 | 55% |
| Nov 15, 2022 | Oppenheimer | maintain | — → Outperform | $7 | 52% |
| Sep 13, 2022 | Piper Sandler | maintain | — → Overweight | $5 | 54% |
| May 3, 2022 | Piper Sandler | maintain | — → Overweight | $7 | 54% |
| Nov 2, 2021 | Oppenheimer | maintain | — → Outperform | $13 | 52% |
| May 4, 2021 | Roth Capital | maintain | — → Buy | $16 | 53% |
| Jan 4, 2021 | Roth Capital | maintain | — → Buy | $16 | 53% |
| Dec 20, 2019 | Northland Capital Markets | maintain | — → Market Perform | $7 | 50% |
| Sep 18, 2019 | Northland Capital Markets | downgrade | Outperform → Market Perform | $0 | 50% |
| Jul 10, 2019 | Northland Capital Markets | upgrade | Market Perform → Outperform | $0 | 50% |
| Feb 5, 2019 | Northland Capital Markets | downgrade | Outperform → Market Perform | $0 | 50% |
| Aug 30, 2018 | Oppenheimer | initiate | — → Outperform | $10 | 52% |
| Jun 22, 2018 | Loop Capital | initiate | — → Buy | $15 | 54% |
Price Target Trend
Apr 23, 2026 Oct 26, 2026
EPS Estimates
0q —
+1y —
0y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days